Previous 10 | Next 10 |
2023-09-29 08:22:20 ET More on Harrow Health Harrow Health's 5-Year Guidance Harrow Health, Inc. 2023 Q2 - Results - Earnings Call Presentation Harrow Health, Inc. (HROW) Q2 2023 Earnings Call Transcript Harrow prices $60 million stock offering; sees Q2 reven...
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced that effective today, it has changed its corporate name from “Harrow Health, Inc.” to “Harrow, Inc.” to align with the Company’s current five-year strategic plan, which includes an e...
2023-09-27 16:14:54 ET Summary Harrow Health has guided to at least $1 billion in revenue by 2027 based on their current portfolio of drugs. The company's deep moat and strong customer relationships make it possible for them to acquire valuable drugs and generate extraordinary ret...
Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced it recently entered into an exclusive development and license agreement with Catalent, the global leader in enabling the development and supply of better treatm...
2023-08-14 17:59:43 ET Gainers: Taysha Gene Therapies ( NASDAQ: TSHA ) +12% . Arcellx ( ACLX ) +10% . Jet.AI ( JTAI ) +10% . CompoSecure ( CMPO ) +9% . Codex ( CDXS ) +9% . Losers: Design Therapeutics ( DSGN ...
2023-08-09 22:35:07 ET Harrow Health, Inc. (HROW) Q2 2023 Earnings Conference Call August 09, 2023 04:45 PM ET Company Participants Jamie Webb - Director-Communications & Investor Relations Mark L. Baum - Chief Executive Officer & Chairman-Board of Directors ...
2023-08-09 16:20:08 ET Harrow Health press release ( NASDAQ: HROW ): Q2 Non-GAAP EPS of -$0.02. Revenue of $33.5M (+43.8% Y/Y) beats by $2.46M . For further details see: Harrow Health Non-GAAP EPS of -$0.02, revenue of $33.5M beats by $2.46M
Second Quarter 2023 and Recent Selected Highlights: Record revenues of $33.5 million, an increase of 44% over $23.3 million in the prior-year quarter and an increase of 28% over $26.1 million in the sequential quarter. GAAP net loss of ($4.2) million. Record adjusted EBITDA of $11.0...
2023-08-01 11:00:00 ET Summary Harrow Health is an eye care pharmaceuticals company. The common stock has been on fire with expectations of rapidly increasing profits. HROW has 2 baby bonds, with one looking particularly interesting given an 11.6% yield to maturity. ...
Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Application (NDA) for VIGAMOX® (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drop for the treatment of bact...
News, Short Squeeze, Breakout and More Instantly...
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 8, 2024 Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2024, on Wednesday, August...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of Retina Specialists (ASRS) Annual Meeting, taking place in Stockholm, Sweden, from July 17-20, 2024. The ASRS Annual Meeting brings tog...
Contract Enhances Purchasing Power for 340B Prime Vendor Program (PVP) Participants; Aligns with Harrow’s Mission to Make Its Products Accessible and Affordable Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, ...